‘‘(2) ACTIVITIES
INCLUDED.—Activities per-
mitted under paragraph (1) include— 
‘‘(A) processing the substance to create ex-
tracts, tinctures, oils, solutions, derivatives, or 
other forms of the substance consistent with the 
information provided as part of a notification 
submitted to the Attorney General under sec-
tion 303(l) or a research protocol filed with the 
application for registration approval; and 
‘‘(B) dosage form development studies per-
formed for the purpose of satisfying regulatory 
requirements of the Food and Drug Adminis-
tration for submitting an investigational new 
drug application. 
‘‘(3) EXCEPTION
REGARDING
MARIHUANA.— 
The authority under paragraph (1) to manufacture 
substances does not include authority to grow mari-
huana.’’. 
(g) TRANSPARENCY REGARDING SPECIAL PROCE-
DURES.—Section 303 of such Act (21 U.S.C. 823), as 
amended by subsection (a), is further amended by adding 
at the end the following: 
‘‘(m) TRANSPARENCY REGARDING SPECIAL PROCE-
DURES.— 
VerDate Sep 11 2014 
20:31 Mar 09, 2022
Jkt 029200
PO 00000
Frm 00028
Fmt 6652
Sfmt 6201
E:\BILLS\H6946.IH
H6946
pamtmann on DSKBC07HB2PROD with BILLS
‘‘(1) IN GENERAL.—If the Attorney General de-
termines, with respect to a controlled substance, that 
an application by a practitioner to conduct research 
with such substance should be considered under a 
process, or subject to criteria, different from the 
process or criteria applicable to applications to con-
duct research with other controlled substances in the 
same schedule, the Attorney General shall make 
public, including by posting on the website of the 
Drug Enforcement Administration— 
‘‘(A) the identities of all substances for 
which such determinations have been made; 
‘‘(B) the process and criteria that will be 
applied to applications to conduct research with 
such substances; and 
‘‘(C) how such process and criteria differ 
from those applicable to applications to conduct 
research with other controlled substances in the 
same schedule. 
‘‘(2) TIMING OF POSTING.—The Attorney Gen-
eral shall make such information public upon mak-
ing such determination, regardless of whether a 
practitioner has submitted such an application at 
that time.’’. 
VerDate Sep 11 2014 
20:31 Mar 09, 2022
Jkt 029200
PO 00000
Frm 00029
Fmt 6652
Sfmt 6201
E:\BILLS\H6946.IH
H6946
pamtmann on DSKBC07HB2PROD with BILLS
SEC. 8. RULEMAKING. 
(a) INTERIM FINAL RULES.—The Attorney Gen-
eral— 
(1) not later than 1 year of the date of enact-
ment of this Act, shall issue rules to implement this 
Act and the amendments made by this Act; and 
(2) may issue such rules as interim final rules. 
(b) PROCEDURE FOR FINAL RULE.—A rule issued by 
the Attorney General as an interim final rule under sub-
section (a) shall become immediately effective as an in-
terim final rule without requiring the Attorney General to 
demonstrate good cause therefor. The interim final rule 
shall give interested persons the opportunity to comment 
and to request a hearing. After the conclusion of such pro-
ceedings, the Attorney General shall issue a final rule in 
accordance with section 553 of title 5, United States Code. 
SEC. 9. GAO REPORT. 
(a) IN GENERAL.—Not more than 4 years after the 
date of enactment of this Act, the Comptroller General 
of the United States shall submit to the Committees on 
Energy and Commerce and the Judiciary of the House 
of Representatives and the Committee on the Judiciary 
of the Senate a report analyzing the implementation and 
impact, to the extent information is available, of perma-
nent class scheduling pursuant to schedule I(e) of section 
202(c) of the Controlled Substances Act, as added by sec-
VerDate Sep 11 2014 
20:31 Mar 09, 2022
Jkt 029200
PO 00000
Frm 00030
Fmt 6652
Sfmt 6201
E:\BILLS\H6946.IH
H6946
pamtmann on DSKBC07HB2PROD with BILLS